source
- Merck's sac-TMT shows promise in Chinese Phase 3 lung cancer trial, may replace chemoMerck and its Chinese partner Kelun-Biotech reported that the antibody-drug conjugate sac-TMT slowed disease progression better than a standard chemotherapy regimen in a Phase 3 trial conducted in…
- Nobel laureate Jennifer Doudna unveils AI-driven platform to design novel gene‑editing enzymesJennifer Doudna, the Nobel laureate who co‑invented CRISPR, announced a new AI‑powered platform for creating gene‑editing proteins in a paper published today in Science. The system uses computation…